Profile data is unavailable for this security.
About the company
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.
- Revenue in GBP (TTM)1.80m
- Net income in GBP-1.63m
- Incorporated2000
- Employees31.00
- LocationFusion Antibodies PLCSpringbank Industrial Estate1 Springbank RoadBELFAST BT17 0QLUnited KingdomGBR
- Phone+44 289 043 2800
- Fax+44 289 002 0446
- Websitehttps://fusionantibodies.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roquefort Therapeutics PLC | -100.00bn | -100.00bn | 2.44m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| ValiRx Plc | 49.78k | -1.92m | 2.62m | 14.00 | -- | 0.607 | -- | 52.64 | -0.0145 | -0.0145 | 0.0004 | 0.0115 | 0.0135 | 0.00 | 0.3528 | 3,555.71 | -54.18 | -48.98 | -53.06 | -49.62 | 100.00 | -- | -4,023.22 | -16,086.59 | 5.30 | -- | 0.003 | -- | 418.54 | -- | 5.99 | -- | -37.39 | -- |
| N4 Pharma PLC | 7.29k | -1.06m | 3.12m | 4.00 | -- | 2.29 | -- | 428.13 | -0.0034 | -0.0034 | 0.00002 | 0.0016 | 0.0071 | -- | 0.0433 | 1,822.50 | -109.21 | -59.59 | -126.18 | -63.90 | -- | -- | -15,363.37 | -67,987.22 | -- | -- | 0.00 | -- | 273.33 | -- | 16.60 | -- | -- | -- |
| Genflow Biosciences PLC | 0.00 | -1.59m | 3.22m | 5.00 | -- | -- | -- | -- | -0.0047 | -0.0047 | 0.00 | -0.0012 | 0.00 | -- | -- | 0.00 | -217.79 | -- | -3,283.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.68 | -- | -- | -- |
| TheraCryf PLC | 0.00 | -1.94m | 5.48m | 9.00 | -- | 0.9098 | -- | -- | -0.004 | -0.004 | 0.00 | 0.0028 | 0.00 | -- | -- | 0.00 | -36.31 | -38.70 | -46.73 | -42.97 | -- | -- | -- | -1,407.46 | -- | -- | 0.00 | -- | -100.00 | -- | 38.13 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.62m | 6.01m | 16.00 | -- | 5.11 | -- | -- | -1.71 | -1.71 | 0.00 | 0.2561 | 0.00 | -- | -- | 0.00 | -109.05 | -87.04 | -131.00 | -102.48 | -- | -- | -- | -- | -- | -21.65 | 0.7545 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.17m | 6.14m | 67.00 | -- | 74.93 | -- | -- | -0.0056 | -0.0056 | 0.00 | 0.0002 | 0.00 | -- | -- | -- | -198.26 | -146.14 | -272.62 | -169.40 | -- | -- | -- | -- | -- | -0.5719 | 0.00 | -- | -- | -- | -26.15 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.55m | 6.90m | 5.00 | -- | 3.07 | -- | -- | -0.0166 | -0.0166 | 0.00 | 0.0163 | 0.00 | -- | -- | 0.00 | -120.92 | -115.31 | -217.21 | -153.87 | -- | -- | -- | -- | 2.20 | -- | 0.00 | -- | -- | -- | -12.76 | -- | -- | -- |
| Fusion Antibodies PLC | 1.80m | -1.63m | 7.96m | 31.00 | -- | 6.30 | -- | 4.42 | -0.0214 | -0.0214 | 0.0225 | 0.0111 | 1.01 | 3.81 | 2.92 | 58,129.03 | -90.74 | -41.50 | -125.54 | -52.23 | 20.20 | 40.19 | -90.29 | -56.92 | 2.73 | -- | 0.0293 | -- | -60.84 | -12.24 | 14.25 | -- | -72.95 | -- |
| ImmuPharma PLC | 0.00 | -2.48m | 10.24m | 6.00 | -- | -- | -- | -- | -0.006 | -0.006 | 0.00 | -0.0013 | 0.00 | -- | -- | 0.00 | -134.30 | -89.81 | -967.42 | -121.17 | -- | -- | -- | -9,895.75 | -- | -21.82 | -- | -- | -- | -- | 15.00 | -- | -56.60 | -- |
| IXICO PLC | 6.44m | -1.55m | 10.43m | 81.00 | -- | 0.8482 | -- | 1.62 | -0.0233 | -0.0233 | 0.0957 | 0.1326 | 0.5019 | -- | 4.29 | 79,456.79 | -12.06 | 0.4889 | -13.67 | 0.5798 | 50.98 | 59.29 | -24.02 | 0.7966 | -- | -- | 0.0219 | 0.00 | -13.49 | -5.28 | -69.86 | -- | -1.85 | -- |
| OptiBiotix Health PLC | 870.00k | -1.81m | 11.62m | 5.00 | -- | 1.31 | -- | 13.36 | -0.0198 | -0.0198 | 0.0089 | 0.0857 | 0.0943 | 2.58 | 1.95 | 174,000.00 | -19.57 | 17.23 | -20.17 | 17.84 | 38.05 | 50.78 | -207.47 | 189.34 | 3.24 | -- | 0.00 | 94.93 | 35.09 | 3.15 | 11.48 | -- | -- | -- |
| Ananda Pharma PLC | 0.00 | -5.54m | 13.11m | 5.00 | -- | 12.14 | -- | -- | -0.0019 | -0.0019 | 0.00 | 0.0003 | 0.00 | -- | -- | 0.00 | -91.47 | -67.39 | -157.42 | -168.38 | -- | -- | -- | -- | -- | -- | 0.4865 | -- | -- | -- | -372.76 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Canaccord Genuity Corp. (Investment Management)as of 09 Apr 2025 | 8.07m | 8.41% |
| Rathbones Investment Management Ltd.as of 21 Mar 2025 | 7.47m | 7.78% |
| Unicorn Asset Management Ltd.as of 09 Apr 2025 | 6.40m | 6.67% |
| Octopus Investments Ltd.as of 31 Aug 2024 | 871.01k | 0.91% |
| Canaccord Genuity Wealth Ltd.as of 30 Sep 2024 | 642.82k | 0.67% |
